Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006–2010

Current Medical Research and Opinion

Volumn 32, Issue 8, 2016, Pages 1399-1407

  Spagnuolo, Philip J ^a   Zhang, Mengxi ^b   Xu, Yaping ^c   Han, Jian ^c   Liu, Shuqian ^b   Liu, Jinan ^b   Lichtveld, Maureen ^b   Shi, Lizheng ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c GENENTECH INC   (United States)

Author keywords

Antiviral; claims database; complications; influenza; oseltamivir

Indexed keywords

ADAMANTANE; ANTIVIRUS AGENT; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; CYSTIC FIBROSIS; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INFANT; INFECTION RISK; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEWBORN; OUTCOME ASSESSMENT; PARKINSON DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEASON; COMPLICATION; INFLUENZA, HUMAN; PRESCHOOL CHILD; STATISTICAL MODEL; TIME FACTOR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; OSELTAMIVIR; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84966709108     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1176016     Document Type: Article

References (45)

1. M.G.Thompson, D.K.Shay, H.Zhou,. Estimates of Deaths Associated With Seasonal Influenza – United States, 1976–2007 (Reprinted from MMWR, vol 59, pg 1057-1062, 2010). JAMA 2010;304:1778–80
2. Centers for Disease Control and Prevention (C.D.C.). Seasonal Influenza (Flu) – People at High Risk of Developing Flu-Related Complications. 2011. http://www.cdc.gov/flu/about/disease/high_risk.htm
3. A.E.Fiore, T.M.Uyeki, K.Broder,. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1–62
4. D.E.Irwin, L.B.Weatherby, W.Y.Huang,. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001;1:8
5. World Health Organization (W.H.O.). Pandemic (H1N1) 2009 – update 112. 2009. http://www.who.int/csr/don/2010_08_06/en/
6. N Principi, S Esposito, R Gasparini, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004;89:1002–7
7. W.P.Glezen How did the 2008–2009 seasonal influenza vaccine affect the pandemic? Clin Infect Dis 2010;51:1380–2
8. A.S.Monto Individual and community impact of influenza. Pharmacoeconomics 1999;16(Suppl 1):1–6
9. T.D.Szucs Medical economics in the field of influenza – past, present and future. Virus Res 2004;103:25–30
10. World Health Organization (W.H.O.). Summary report of a High-Level Consultation: New Influenza A (H1N1). Geneva: W.H.O., 2009
11. M.Keech, A.J.Scott, P.J.Ryan The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998;48:85–90
12. T.P.Ng, K.H.Pwee, M.Niti, L.G.Goh Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore 2002;31:182–8
13. F.Y.Aoki, M.D.Macleod, P.Paggiaro,. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123–9
14. J.A.Hedrick, A.Barzilai, U.Behre,. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410–17
15. K.G.Nicholson, F.Y.Aoki, A.D.Osterhaus,. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845–50
16. The M.I.S.T. (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877–81
17. R.J.Whitley, F.G.Hayden, K.S.Reisinger,. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127–33
18. L.Kaiser, C.Wat, T.Mills,. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–72
19. M.A.Hernan, M.Lipsitch Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011;53:277–9
20. N.J.Cooper, A.J.Sutton, K.R.Abrams,. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235
21. W.A.Blumentals, X.Song The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med 2007;9:23
22. P.A.Piedra, K.L.Schulman, W.A.Blumentals Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009;124:170–8
23. J.G.Gums, E.M.Pelletier, W.A.Blumentals Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008;9:151–61
24. B.L.Nordstrom, I.Sung, P.Suter, P.Szneke Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005;21:761–8
25. J.E.Loughlin, T.D.Alfredson, A.N.Ajene,. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clin Ther 2002;24:1786–99
26. Centers for Disease Control and Prevention (C.D.C.). “Have You Heard?” – CDC Recommendations for Influenza Antiviral Medications Remain Unchanged. 2011. http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral2.html
27. T.Jefferson, M.A.Jones, P.Doshi,. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012;1:CD008965
28. L.G.Hansen, S.Chang Health Research Data for the Real World: The MarketScan Databases. The Truven Health Analytics, 2011
29. A.E.Fiore, A.Fry, D.Shay,. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1–24
30. T.Uyeki Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 2009;361:e110
31. J.Loughlin, N.Poulios, P.Napalkov,. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003;21:273–83
32. C.R.Meier, P.N.Napalkov, Y.Wegmuller,. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:834–42
33. A.M.Connolly, R.L.Salmon, B.Lervy, D.H.Williams What are the complications of influenza and can they be prevented – experience from the 1989 epidemic of H3n2 influenza-A in general-practice. Br Med J 1993;306:1452–4
34. C.Enger, B.L.Nordstrom, B.Thakrar, S.Sacks, K.J.Rothman Health outcomes among patients receiving oseltamivir. Pharmacoepidem Dr S 2004;13:227–37
35. H.Moses, D.H.Matheson, E.R.Dorsey,. The anatomy of health care in the United States. JAMA 2013;310:1947–64
36. J.Zhang, F.Y.Kai What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690–1
37. C.O.Schmidt, T.Kohlmann When to use the odds ratio or the relative risk? Int J Publ Health 2008;53:165–7
38. G.Zou A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–6
39. S.Heinonen, H.Silvennoinen, P.Lehtinen,. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis 2010;51:887–94
40. A.Rodriguez, E.Diaz, I.Martin-Loeches,. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011;66:1140–9
41. L.Shi, M.Loveless, P.Spagnuolo,. Antiviral treatment of influenza in children: a retrospective cohort study. Adv Ther 2014;31:735–50
42. Chan M, Lim PL, Chow A, et al. Surveillance for Clostridium difficile infection: ICD-9 coding haspoor sensitivity compared to laboratory diagnosis in hospital patients, Singapore. PLoS One 2011;6: e15603. doi: 10.1371/journal.pone.0015603
43. R.Keren, A.Wheeler, S.E.Coffin,. ICD-9 codes for identifying influenza hospitalizations in children. Emerging Infect Dis 2006;12:1603–4
44. K.A.Feemster, K.H.Leckerman, M.Middleton,. Use of administrative data for the identification of laboratory-confirmed influenza infection: the validity of influenza-specific ICD-9 Codes. J Pediatr Infect Dis Soc 2013;2:63–6
45. E.Amodio, F.Tramuto, C.Costantino,. Diagnosis of influenza: only a problem of coding? Med Princ Pract 2014;23:568–73